CATO vs JAZZ · rev $336.6M vs P/E 1988, rev $2.28B
Cato Corporation (CATO) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
Cato Corporation (CATO) is a apparel retail company listed on US.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Latest reported CATO revenue for 2026-08-01 was $336.6M. Net income was $10.5M. Revenue was up 96.7% from 2026-05-02 to 2026-08-01. CATO currently screens at market cap $64.7M.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
CATO currently screens at market cap $64.7M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the CATO and JAZZ stock pages for the full models.
Not investment advice.